DOCSLIB.ORG

08001 Prelim Prog for Print.Qxp

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
08001 Prelim Prog for Print.Qxp The content in this document was updated on June 13. For the most up-to-date information, CLICK HERE. Boston, Massachusetts Annual Meeting TH Boston Convention & 44 Exhibition Center June 22-26, 2008 PROGRAM CHAIRPERSON Jeffrey W. Sherman, MD, FACP IDM Pharma, Inc. Program Chairperson Boston – The City of Firsts As our nation’s oldest major city, Boston is home to the first: • University Medical Firsts: • Public school • First time ether was used as an anesthetic during an • Public Health operation at Massachusetts Commission General Hospital in 1846 • Subway station • First kidney transplant performed in 1954 • Free library • First pediatric open heart • Paid fire and police surgery performed at departments Children's Hospital in 1967 Jeffrey (Jeff) W. Sherman, MD, FACP, Chief Medical Officer and Senior Vice President of Research & Development, IDM Pharma, Inc. Before joining IDM Pharma, Jeff was Vice President of Clinical Science at Takeda Global Research and Development. He has also worked as the Chief Medical Officer and Executive Vice President at NeoPharm, Inc. He has also held positions at Searle/Pharmacia Research and Development, including Director, Senior Director, and Executive Director of Clinical Research. There he managed clinical development activities for a variety of therapeutic areas, including infectious diseases, women’s health, sleep, and central nervous system. Jeff went on to lead company-wide oncology clinical research as Executive Director, Clinical Research and then oncology medical marketing as Head, Oncology Global Medical Operations. Prior to joining Searle/Pharmacia, Jeff worked at Bristol-Myers Squibb in clinical pharma- cology and clinical research. Jeff received his MD from Rosalind Franklin University/Chicago Medical School. He completed an internship and resi- dency in internal medicine at Northwestern University, where he served as chief medical resident. Additionally, he completed a fellowship in infectious diseases with an interest in immunocompromised patients at the University of California-San Francisco (UCSF) and was a research associate in allergy and immunology at the Howard Hughes Medical Institute at UCSF. Jeff is an Adjunct Assistant Professor of Medicine at the Northwestern University Feinberg School of Medicine, Diplomat of the National Board of Medical Examiners and American Board of Internal Medicine, and a member of the DIA Board of Directors. He received a DIA Outstanding Service Award in 2001. Table of Contents 1 Chairperson’s Message 9 Getting to, and around, Boston 115 Exhibiting Companies 2 Keynote Speakers 10 General Information 137 Tutorial Pricing Guide Dennis A. Ausiello, MD, Harvard Medical School/ including Continuing Education and Massachusetts General Hospital Contact Information 138 Hotel Information Kathy Giusti, MBA, Multiple Myeloma Research Hotel Reservation Form, Please monitorFoundation/Multiple www.diahome.org Myeloma Researchfor program Consortium updates and12 onlineTutorials registration. Hotel Locator Map 3 Program Committee 25 Meeting Schedule 140 Optional Tours 4 Networking Reception Session Details Tour Descriptions 6 Meeting Highlights 32 Saturday, June 21 – Monday, June 23 143 Tour Reservation Form Multitrack Plenary Session, Hot Topics, Megatracks 53 Tuesday, June 24 144 Attendee Registration Form 8 About the Annual Meeting/ 78 Wednesday, June 25 Benefits of Membership 105 Thursday, June 26 Invitation to DIA’s 44th Annual Meeting June 22-26, 2008 Boston, MA, USA Dear Colleague, Welcome to Boston, a major national and international city of technology, science, and higher education, making it an attractive location for information technology, research and development, and biotechnology companies. Oliver Wendell Holmes called it "The Hub of the Universe." It has also been deemed "The Athens of America." To many it is known as "Beantown." Whatever name you choose, Boston is a unique city that has played a major role in the American experience. More than 90 colleges and universities call the greater Boston area home–a higher concentration than any other part of the world. From distinguished physicians and medical researchers, to world-class athletes and per- formers, Boston is a host to some of the world's most elite and accomplished people. It is only fitting that DIA has chosen Boston as the site for its 44th Annual Meeting. Like Boston, the DIA Annual Meeting is rich in history, forward thinking, passionate, and intellectually stimulating; there is something for everyone. The DIA Annual Meeting rep- resents the most significant means for advancing our objectives via our multidisciplinary focus, international reach, and neutral forums. The 44th Annual Meeting will offer innov- ative ideas, provide answers to new questions, and help the pharmaceutical industry redefine the development, regulation, surveillance, and marketing of pharmaceuticals. This year’s event features keynote addresses by Dennis A. Ausiello, MD, Jackson Professor of Clinical Medicine at Harvard Medical School and Chief of Medicine at Massachusetts General Hospital (MGH), and Kathy Giusti, Founder and Chief Executive Officer, Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC). Dr. Ausiello is a nationally recognized leader in academic medicine who has made significant contributions to epithelial biology, particularly in the areas of membrane protein trafficking, ion channel regulation, and signal transduction. Ms. Giusti is world renowned for her tireless work on behalf of multiple myeloma research. Conference participants will benefit from nearly 400 sessions across 26 content-area tracks, with more than 1,000 speakers, and over 450 exhibitors showcasing the indus- try’s latest products and services. Networking is also a hallmark of the DIA Annual Meeting–from the daily continental breakfasts and afternoon refreshment breaks to the more formal Networking Receptions. Your invitation to participate is an invitation to explore the very heart of our work. See you in Boston! Jeffrey (Jeff) W. Sherman, MD, FACP 44th Annual Meeting Program Chair “The meeting far exceeded my expectations. It is THE BEST professional conference I have attended in recent years.” 1 2007 Annual Meeting Attendee Plenary Session Keynotes Dennis A. Ausiello, MD, is the Jackson Professor of Clinical Medicine at Harvard Medical School, and Chief of Medicine at Massachusetts General Hospital (MGH). He received his undergraduate degree from Harvard College and his medical degree from the University of Pennsylvania. He has made a sub- stantial contribution to knowledge of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction. He has published numerous articles, book chapters, and textbooks and served as the co-editor of Cecil’s Textbook of Medicine, in its 22nd and 23rd edition. A nationally recognized leader in academic medicine, Dr. Ausiello was elected to the Institute of Medi- ine of the National Academy of Science in 1999 and the American Academy of Arts and Sciences in 2003. He has written for the New York Times, the Wall Street Journal, and the Boston Globe on health sub- jects, including human genetics, clinical trials, and the relationship between the academy and industry. Dr. Ausiello served as Chief of the MGH Renal Unit and oversaw its development into one of the most sought after research and training programs in the world. As Chief of Medicine at Massachuetts General Hospital, a position he has held since 1996, he leads one of the strongest Departments of Medicine in the country with a clinical, research and education budget exceeding $500 million annually. He is closely involved with the Partners HealthCare System, linking the resources of the Massachusetts - General Hospital, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute to provide com- prehensive health care. He oversees the training of more than 150 house officers, 500 graduate students and postdoctoral fellows, and dozens of students at Harvard Medical School, many of whom have gone on to careers as physician-scientists. Dr. Ausiello was also Director of the MD/PhD Program at Harvard Medical School and the Massachusetts Institute of Technology until 1999. He served as Chairman of the Executive Committee on Research of the Massachusetts General Hospital where he oversaw a research budget of $350 million annually. As an internationally recognized scientist, Dr. Ausiello has been the recipient of two MERIT awards from the National Institutes of Health and has served as a council member of the National Institute of Diabetes, Digestive and Kidney Diseases Advisory Council and the National Advisory Council on Aging. Understanding the need for partnerships between the academy and industry, Dr. Ausiello also serves in a variety of advisory roles beyond his aca- demic affiliations. Dr. Ausiello serves on the Board of Directors of Pfizer, Inc., and MicroCHIPS, a drug-sensing and delivery company. In addition, Dr. Ausiello is also a member of the Scientific Advisory Boards of Promedior, Proventys and Pulmatrix. Dr. Ausiello is particularly interested in the training of inquisitive physicians and translational investigators, and is the architect and director of the recently implemented Harvard initiative in Patient-Associated Science: Training, Education, Understanding, and Research (PASTEUR) – a novel edu- cational program designed to introduce Harvard medical students and select Harvard undergraduates and graduate students to the excitement,
Load more

Recommended publications
  • Double Line Image Rotation Amir Hossein Ashtari, Member, IEEE,Mdjannordin,Member, IEEE, and Seyed Mostafa Mousavi Kahaki, Member, IEEE
    3370 IEEE TRANSACTIONS ON IMAGE PROCESSING, VOL. 24, NO. 11, NOVEMBER 2015 Double Line Image Rotation Amir Hossein Ashtari, Member, IEEE,MdJanNordin,Member, IEEE, and Seyed Mostafa Mousavi Kahaki, Member, IEEE Abstract— This paper proposes a fast algorithm for rotating rotation transformation has been expressed in (2). The direct images while preserving their quality. The new approach rotates determination of the rotated points is a one-pass method. images based on vertical or horizontal lines in the original image and their rotated equation in the target image. The proposed xr cos α − sin α xt method is a one-pass method that determines a based-line = . (2) yr sin α cos α yt equation in the target image and extracts all corresponding pixels on the base-line. Floating-point multiplications are performed Determining the rotated point directly using a single to calculate the base-line in the target image, and other line function such as (2) is a one-pass technique, whereas cal- coordinates are calculated using integer addition or subtraction and logical justifications from the base-line pixel coordinates in culating the rotated point using multiple functions such the target image. To avoid a heterogeneous distance between as (3), (4), and (5) is a multi-pass technique. Compared with rotated pixels in the target image, each line rotates to two multi-pass methods, one-pass methods are simple and usually adjacent lines. The proposed method yields good performance more accurate [2], [5]. However, although one-pass methods in terms of speed and quality according to the results of an are accurate, they are still inefficient because multiple analysis of the computation speed and accuracy.
    [Show full text]
  • 9894 Pharma Tech Media Planner V6 2007
    www.pharmtech.com years 1977– 2007 30ANNIVERSARY CELEBRATING 30 YEARS AS THE 2007 INDUSTRY’S MOST AUTHORITATIVE SOURCE Media Planner years 1977–2007 ANNIVERSARY years 1977–2007 ANNIVERSARY THE PHARMACEUTICAL TECHNOLOGY BRAND PUBLISHER’S STATEMENT Pharmaceutical Technology’s authoritative reputation and powerful brand recognition within the pharmaceutical/biopharmaceutical development & manufacturing marketplace will help you establish and maintain your own strong brand among pharma industry decision makers. A circulation of 38,667 BPA-qualified subscribers* and unmatched peer written and reviewed editorial make Pharmaceutical Technology an invaluable resource within top pharma companies, as well as small, specialty and biotech pharma companies spending billions each year on pharmaceutical development and manufacturing. Please celebrate with us as Pharmaceutical Technology marks its 30th Anniversary as the industry leader. —Michael Tracey, Publisher % 90 of readers rated Pharmaceutical Technology as important or very important to them as a professionalˆ EDITORIAL MISSION Pharmaceutical Technology publishes authoritative, reliable, and timely peer-reviewed research and expert analyses for scientists, engineers, technicians, and managers engaged in process development, manufacturing, formulation, analytical technology, packaging and regulatory compliance in the pharmaceutical and biotechnology industries. —Douglas McCormick, Editor in chief www.pharmtech.com *BPA June 2006 Statement ^2006 Readership Study Conducted by Advanstar Research
    [Show full text]
  • Experimental and Computational Requirements for Post-Genomic Integrative Cellular Physiology John Wikswo
    VANDERBILT INSTITUTE FOR INTEGRATIVE BIOSCIENCE RESEARCH AND EDUCATION (VIIBRE) Experimental and Computational Requirements for Post-Genomic Integrative Cellular Physiology John Wikswo Instrumenting and the Single Cell Controlling 1 Topics • The advantages of micro/nanoscale instruments • Cellular complexity • The need for closed-loop control • How to identify early manifestations of disease – Modeling – Interactive, dynamical analysis – Mining dynamics data 2 Topics • The advantages of micro/nanoscale instruments • Cellular complexity • The need for closed-loop control • How to identify early manifestations of disease – Modeling – Interactive, dynamical analysis – Mining dynamics data 3 Reductionism in Science Thermodynamics Bulk solids Anatomy Statistical Devices Physiology mechanics Continuum Organ Molecular/atomic models dynamics Cell Microscopic Electrodynamics models Protein Quantum Atomic physics Genome Chromodynamics 4 Historical Evolution of Spatial Resolution in Biology and Physiology 3000 • Genomics Molecular Physiology Biology Cell 2000 –Structural Molecule Cell genomics 1000 X-Ray / SEM / STM … Optical microscope 0 • Proteomics Tissue –Structural -1000 Magnifying glass proteomics -2000 –Functional HistoricalYears Time, proteomics Unaided eye AnimalAnimal -3000 … • What is next? 10-9 10-6 10-3 100 Resolution, Meters 5 TheThe raterate atat whichwhich DNADNA sequencessequences beganbegan accumulatingaccumulating waswas exponentialexponential 14,000,000 ~13 million 12,000,000 sequence entries 10,000,000 in GenBank 8,000,000 Nearly 13 billion 6,000,000 bases from Human Genome Rapid DNA 4,000,000 Project begun ~50,000 species sequencing invented 2,000,000 GB 0 1965 1970 1975 1980 1985 1990 1995 2001 Year National Library of Medicine Courtesy of Mark Boguski 6 Hypotheses I and II I. The explosion in genomic and proteomic knowledge and measurement techniques will revolutionize the early detection of diseases II.
    [Show full text]
  • How to Win Back America's Transit Riders
    Who’sDrew to add cover On Board 11 Charts done 2019 How to Win Back America’s Transit Riders TransitCenter works to improve public transit in ways that make cities more just, environmentally sustainable, and economically vibrant. We believe that fresh thinking can change the transportation landscape and improve the overall livability of cities. We commission and conduct research, convene events, and produce publications that inform and improve public transit and urban transportation. For more information, please visit www.transitcenter.org. Publication Date: February 2019 1 Whitehall Street, 17th Floor, New York, NY 10004 www.TransitCenter.org @transitcenter Facebook.com/transitctr Who’s On Board 2019 How to Win Back America’s Transit Riders Acknowledgments Steven Higashide and Mary Buchanan of TransitCenter are the authors of this report. David Bragdon and Tabitha Decker provided additional writing and editorial review. The authors are grateful for thoughtful review from Evelyn Blumenberg, Nicholas Klein, Alan Lehto, Tom Mills, Michelle Poyourow, Jarrett Walker, Aaron Weinstein, and TransitCenter’s Jon Orcutt and Hayley Richardson. Resource Systems Group (RSG) served as the lead research consultant, conducting focus groups, developing the survey questionnaire, and analyzing survey results. The authors gratefully acknowledge RSG’s project manager Ben Cummins. Greg Spitz and Alex Levin of RSG and Jed Lam of Aeffect also contributed to the research. The authors thank Emily Drexler of the Chicago Transit Authority for assistance with recruiting for focus groups, as well as Linda Young and Preeti Shankar of the Center for Neighborhood Technology for providing AllTransit data. Contents Executive Summary 1 All Transit Ridership is Local 6 Findings 14 1.
    [Show full text]
  • Memorandum JUL 1 6 201D
    Memorandum Subject Date Additional Quota Letters Received by July 15, 2010 (DFN: 630-08.2) JUL 1 6 201D To From Christine A. Sanncrud. Ph.D., Chief "Barbar• J.Illoockholdt, Chief Drug & Chemical Evaluation Section Regul• torn Section Office of Diverison Control Off cL rl Diversion Control On July 15. 2010, this section received your e-mail requesting a review of seventeen (17) quota applications from sixteen (16) registered manufacturers to determine if there arc any pending administrative/legal actions against these applicants and to advise ODE of the findings. ODOR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations. QUOTA APPLICANTS wan NO ADVERSE OR DEROGATORY INFORMATIO N Novartis Consumer I lealth Lincoln (10345) (b)(4);(b)(7)(E) Baxter (10346) Generics Bidco li bda Vintage (10347) Noramco Delaware (10348) Pharmaceuticals International inc. (10349) Pharmedium (10351) Pharmedium (10352) Rhodes (10356) Bio-Pharm (10357) Patheon (10358) Patheon (10359) Watson (10361) B & B (10363) lospira. Inc. NC (10364) Epic Pharma (10366) Mallinckrodt I lobart (10367) Chemtos (10368) Vol. II Page 55 2 Per consultation with the field offices. DEA does not have sufficient grounds to limit, restrict. or deny quota requests from these registrants. Based on this information. ODG suggests that you proceed with the completion of the quota applications. If you have any questions pertaining to this information. please feel free to contact me (b)(6);(b)(7)( or SC C) (b)(6);(b)(7)(C) Vol. II Page 56 Memorandum Subject Date Additional Quota Letters Received as of July 19, 201() (DFN: 630-08.2) stir 2 8 2010,., To Fr ,./"./ Christine A.
    [Show full text]
  • National Assessment of Urban Rail Noise
    , REPORT NO UMTA-MA-06-0099-79-2 JJ DEPARTMENT OF NATIONAL ASSESSMENT OF TRANSPORTATION URBAN RAIL NOISE J UN 6 */9/y Gregory Ch i s holm LIBRARY Herbert Boge n Michael Di nn i ng Michael Prim eggi a . of T ra ns port a t i o n U S . department Research and Special P rogr ams Admi n i s t r a t i o n Transportati on Sys terns Cen ter i 021 42 Cambr dge , MA Of TRaa. MARC H 1979 FINAL REPORT DOCUMENT IS AVAILABLE TO THE U.S. PUBLIC THROUGH THE NATIONAL TECHNICAL INFORMATION SERVICE, SPRINGFIELD, VIRGINIA 22161 Prepared for U.S. DEPARTMENT OF TRANSPORTATION URBAN MASS TRANSPORTATION ADMINISTRATION Office of Technology Development and Deployment Office of Rail and Construction Technology Washington DC 20590 NOTICE This document is disseminated under the sponsorship of the Department of Transportation in the interest of information exchange. The United States Govern- ment assumes no liability for its contents or use thereof. NOTICE The United States Government does not endorse pro- ducts or manufacturers. Trade or manufacturers' names appear herein solely because they are con- sidered essential to the object of this report. Technico! Report Documentation Pag 1 . Report N o 2 Government Accession No. 3. Recipient s Cotolog No. UMTA-MA-06-0Q9 9-7 9-2 S 5. Report Date natioVal assessment OF URBAN RAIL NOISE March 1979 6. Performing Orgomzotion Code 8. Performing Orgoni zotion Report No 7. Author s' Gregory Chisholm, et al. DOT-TSC-UMTA-7 9-10 9. Performing Orgom lotion Nome and Address 10 Work Unit No IT RAIS) U.S.
    [Show full text]
  • East-West Corridor High Capacity Transit Plan Rapid Transit Evaluation Results
    East-West Corridor High Capacity Transit Plan Rapid Transit Evaluation Results About the Corridor The AECOM consultant team conducted a high-level analysis of commuter rail, light rail transit (LRT), streetcar and bus rapid transit (BRT) to determine the most appropriate mode for the East- West Corridor. Based on the corridor fit, ridership capacity, cost per mile to build/operate and available right-of-way, BRT will move forward for more detailed analysis. This fact sheet provides, in more detail, how BRT and LRT compared and why BRT was determined to be the best fit. BRT with LRT Screening Results Below are the similarities and differences between bus rapid transit (BRT) and light rail transit (LRT). Features Bus Rapid Transit (BRT) Light Rail Transit (LRT) Service Frequency Frequent service during peak hrs. (5–15 min.) Frequent service during peak hrs. (5–15 min.) Typical Corridor Length 5–25 mi. 10–20 mi. Range of Operating Speed 25–55 MPH 30–55 MPH Right-of-Way Dedicated lanes and/or mixed traffic Dedicated lanes with overhead electrical systems Typical Station Spacing ½ and one mile apart One mile apart, outside of downtowns Level boarding at high-quality stations Level boarding at high-quality stations Vehicle Types 40- or 60-ft. buses that have multiple doors 1–3 car trains; low floor vehicles Technology Traffic signal priority Traffic signal priority Real-time passenger info Real-time passenger info Off-board fare payment Off-board fare payment Typical Operating Cost per Hr. $100–$200 $200–$400 Typical Capital Cost per Mi. $2.5 million–$20 million $140 million+ Ridership Capacity by Mode Best Poor Current East-West Corridor Ridership (6.9k–8.7k riders) Modern Streetcar Light Rail Transit (1.5k–6k riders) (20k–90k riders) Bus Rapid Transit (4k–15k riders) Commuter Rail (3k–20k riders) Ridership Mode Capacity by 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 50,000 The chart above demonstrates that BRT and commuter rail both have the needed capacity to meet ridership needs.
    [Show full text]
  • Pharmaceutical Research and Manufacturers of America – Phrma
    The Short-Term and Long-Term Competitive Impact of Authorized Generics A Report for the Federal Trade Commission October 28, 2009 TABLE OF CONTENTS INTRODUCTION ........................................................................................................................... 1 DISCUSSION .................................................................................................................................. 3 I. LONG-TERM COMPETITIVE HARM IS UNLIKELY ................................................... 3 A. Unsupported Foreclosure Claims Have Been Made For Nearly Two Decades .................................................................................................................... 4 B. Marketplace Realities Undercut The Long-Tenn Foreclosure Theory .................... 7 1. Sales and Profitability Are Growing ........................................................... 7 2. Wall Street Valuations Are Growing ........................................................ 10 II. THE FTC PRICING ANALYSIS SHOWS $880 MILLION IN CONSUMER SAVINGS .......................................................................................................................... 14 III. CONSUMER SAVINGS SHOULD BE MEASURED USING WHOLESALE DATA AND WEIGHTED AVERAGE PRICES .............................................................. 17 A. The Wholesale Data Carries Far More Weight.. .................................................... 17 B. Average Drug Prices Should Be Volume-Weighted ............................................. 19 IV.
    [Show full text]
  • Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Paten
    Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patents Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent DrugsDrug Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under
    [Show full text]
  • Clinical Research Services
    Clinical Research Services Advancing the future of medicine through research. Who We Are Experience Clinical Research Services is a department within Clinical Research Services has been involved CHI St. Alexius Health in Bismarck, ND. We are fully in clinical research since 1987. Our professional dedicated to providing research support services staff has more than 180 years of combined to physicians within our region and the valued experience in clinical trials. We are committed patients they serve. to providing outstanding service to ensure the success of every project. CHI St. Alexius Health is a tertiary care facility affiliated with PrimeCare, a health group which Our involvement in inpatient and outpatient combines the most experienced, trusted, and phase II-IV clinical and device research studies has proven medical leaders in the area. PrimeCare is contributed substantially to the approval of new comprised of a network which includes more than drugs and treatments. You should carefully consider 190 physicians in private and institutional practice, both the benefits and the risks of participation including: CHI St. Alexius Health, Mid Dakota Clinic, before enrolling in a study. The Bone & Joint Center, and other affiliated area physicians. Many of these physicians are actively Previous clinical study trials: involved as investigators for clinical trials. • Oncology • Orthopaedic • Rheumatology • Diabetes Our clinical research team is committed to providing: • Neurology • Weight loss • Rapid study start-up • Cardiology • Pain • Pro-active patient enrollment • Urology • Men’s Health • Clean data submission • Gastroenterology • Women’s Health • Highly experienced principal • Infectious Disease • Medical Devices investigators • Pediatric • Initial training and continuing education for all support personnel Sponsors Patient Demographics Abbott Laboratories Characteristics of our patients include Acorda Therapeutics, Inc.
    [Show full text]
  • Dr. Richard Rozek
    Dear Ms. Overstreet: I am interested in being considered for the vacancy on the Glynn Brunswick Memorial Hospital Authority. Per the instructions with the vacancy announcement, I attached a copy of my vita to the letter. I am an economist with a specialty in health care economics. I have worked on competition, regulation, contract, and tax issues in health care during my career in academic, federal government, and private sector positions. I have written articles on health care issues and testified in major health care litigations. I have owned a home on Jekyll Island since 1993. Please let me know if you need additional information. Sincerely, Richard P. Rozek, Ph.D. RICHARD P. ROZEK, PH.D. CONTACT INFORMATION Redacted Jekyll Island, GA 31527 Phone: 912 Redacted Redacted gmail.com BACKGROUND Dr. Rozek received a B.A. degree in Mathematics with honors from the College of St. Thomas, a M.A. degree in Mathematics from the University of Minnesota, and M.A. and Ph.D. degrees in Economics from the University of Iowa. Dr. Rozek began his professional career as an Assistant Professor at the University of Pittsburgh where he taught courses in industrial organization, mathematical economics, and microeconomic theory. Dr. Rozek then worked for over six years in the Bureau of Economics at the Federal Trade Commission in a series of senior staff positions including Deputy Assistant Director for Antitrust. While at the FTC, Dr. Rozek evaluated antitrust and regulatory issues in electric and gas utilities, oil pipelines, soft drinks, for-profit and nonprofit hospitals, motion pictures, pharmaceuticals, and information industries.
    [Show full text]
  • Inside This Issue
    Issue No. 225 FDA Counting on Global Strategy April 2011 To Better Secure Supply Chain The FDA’s work toward tighter supply chain control through INsIde thIs Issue international regulatory cooperation is falling short, but a new global strategy may speed up the agency’s progress, a top FDA Sterility issues lead to an- official says. other J&J recall ........Page 2 The next several years are critical in the agency’s transformation FDA zeroes in on compli- to a “global agency,” John Taylor, the FDA’s acting principal deputy ance history to make in- commissioner, said March 14 at a Pew Charitable Trusts conference spection decisions ....Page 3 in Washington, D.C., on drug supply safety. To achieve adequate supply chain control, Taylor said, the FDA 483 Insider ..............Page 5 needs novel and updated enforcement tools, a global alliance of reg- ulators, new authorities to create proactive tools for product safety, APP recalls oncologic irino- tecan over fungal contami- (See Global, Page 2) nation .......................Page 6 McNeil Gets Consent Decree After Pharma manufacturing in Period of Manufacturing Woes Japan largely spared by The FDA has said enough is enough to McNeil Consumer Health- quake ........................Page 8 care over its repeated manufacturing problems, issuing a consent decree that indefinitely closes one plant and places oversight over two others. Bill would increase penal- ties for prescription drug The agency said the Johnson & Johnson subsidiary, which has thefts ......................Page 10 been plagued with recalls of its OTC drugs relating to cGMP viola- tions, will not be able to reopen its troubled Fort Washington, Pa., Dakota labs gets warning plant until a litany of changes have been made.
    [Show full text]